| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 02/22/2000 | US6028055 Use in treatment or prophylaxis of various pathological conditions associated with water or electrolyte imbalance |
| 02/22/2000 | US6028054 Method for increasing bioavailability of oral pharmaceutical compositions |
| 02/22/2000 | US6028053 Peptide inhibitors of a phosphotyrosine-binding domain containing protein |
| 02/22/2000 | US6028052 Treating NIDDM with RXR agonists |
| 02/22/2000 | US6028051 Administering single dose of lysostaphin analogue and lysostaphin for treating endocarditis, bacterimia, kidney infection, lung infection, skin infection, bone infection, burn wound infections, infection of prosthetic devices |
| 02/22/2000 | US6028050 Method for increasing platelets by administering soluble interleukin-6 receptor |
| 02/22/2000 | US6027935 Gene up-regulated in regenerating liver |
| 02/22/2000 | US6027927 Human trk receptors and neurotrophic factor inhibitors |
| 02/22/2000 | US6027922 Human foam cells and methods for preparing them, monoclonal antibodies to said foam cells and their pharmaceutical and diagnostic use |
| 02/22/2000 | US6027921 Chimeric proteins for use in transport of a selected substance into cells and DNA encoding chimeric proteins |
| 02/22/2000 | US6027919 BMP-12 and BMP-13 proteins and DNA encoding them |
| 02/22/2000 | US6027917 Bone morphogenetic protein (BMP)-17 and BMP-18 compositions |
| 02/22/2000 | US6027916 Galectin 9 and 10SV Polynucleotides |
| 02/22/2000 | US6027914 Cytokine response (cr) genes |
| 02/22/2000 | US6027901 CYP7 promoter-binding factors |
| 02/22/2000 | US6027892 Compositions and methods for reducing radiation and drug resistance in cells |
| 02/22/2000 | US6027890 Detecting ligand binding by incubating tagged members with biological sample, separating bound from unbound members, cleaving tag, then detecting by non-fluorescent spectroscopy or potentiometry |
| 02/22/2000 | US6027888 Methods for producing soluble, biologically-active disulfide-bond containing eukaryotic proteins in bacterial cells |
| 02/22/2000 | US6027887 Screening for preneoplastic/neoplastic disease using a nucleic acid based assay to determine whether mn oncogene expression is present in a vertebrate; and if present, determining if vertebrate is at risk of neoplastic disease |
| 02/22/2000 | US6027878 A nucleic acid sequence; diagnosis of helicobacter infections, ulcers and gastrointestinal disorders |
| 02/22/2000 | US6027734 To provide protection against pneumococcal colonization and systemic infection, intranasally administering a composition consisting essentially of pneumococcal surface protein a or a fragment containing a protection-eliciting epitope |
| 02/22/2000 | US6027731 Pertussis toxin induced lymphocytosis |
| 02/22/2000 | US6027720 G-CSF conjugate |
| 02/22/2000 | US6027712 Immunotherapy of inflammatory sinus and ear disease |
| 02/22/2000 | US6027711 Structurally determined metallo-constructs and applications |
| 02/22/2000 | CA2170607C Difluoro statone antiviral analogs |
| 02/22/2000 | CA2091882C Gene therapy for cystic fibrosis |
| 02/22/2000 | CA2071630C Hybrid protein c |
| 02/22/2000 | CA2071625C A pharmaceutical preparation containing a thrombolytically active substance |
| 02/22/2000 | CA2063303C Preparation of virus-free immunoglobulins |
| 02/22/2000 | CA2004532C Peptide derivatives |
| 02/22/2000 | CA2003455C Immunotherapy involving cd28 stimulation |
| 02/22/2000 | CA1340911C Antiherpes cyclic peptides |
| 02/22/2000 | CA1340910C Fibronectin binding protein |
| 02/22/2000 | CA1340908C Methods of producing secreted receptor analogs and biologically active peptide dimers |
| 02/22/2000 | CA1340906C Fibronectin binding protein as well as its preparation |
| 02/22/2000 | CA1340904C Amino acid derivative anticonvulsant |
| 02/22/2000 | CA1340902C Amino acid derivative anticonvulsant |
| 02/17/2000 | WO2000008213A1 Oligomers which inhibit expression of collagen genes |
| 02/17/2000 | WO2000008199A1 Molecular cloning of a 7tm receptor (gpr31a) |
| 02/17/2000 | WO2000008197A1 Method for the production of an antibiotic agent |
| 02/17/2000 | WO2000008196A2 Urate oxidase |
| 02/17/2000 | WO2000008174A1 β-CASEIN EXPRESSING CONSTRUCTS |
| 02/17/2000 | WO2000008173A1 Identification and functional characterization of a novel ribosomal s6 protein kinase |
| 02/17/2000 | WO2000008171A1 N-acetylglycosaminyl transferase genes |
| 02/17/2000 | WO2000008158A2 Molecules designated ldcam |
| 02/17/2000 | WO2000008157A2 Human anion transporter genes atnov |
| 02/17/2000 | WO2000008156A2 Dna replication- and repair-associated proteins |
| 02/17/2000 | WO2000008155A2 Human receptor-associated proteins |
| 02/17/2000 | WO2000008153A2 Arf-p19, a novel regulator of the mammalian cell cycle |
| 02/17/2000 | WO2000008152A1 Novel orphan cytokine receptors |
| 02/17/2000 | WO2000008151A1 Calcium/calmodulin dependent kinase and an alternative splice product thereof |
| 02/17/2000 | WO2000008150A1 Method for treatment of invasive cells |
| 02/17/2000 | WO2000008147A1 Genes involved in the molecular paths for tumour suppression and /or resistance to viruses |
| 02/17/2000 | WO2000008146A2 Novel tension-dependent potassium channel and the use thereof in the development of new therapeutic agents |
| 02/17/2000 | WO2000008145A2 Novel genes in control of hematopoiesis |
| 02/17/2000 | WO2000008144A1 Dna encoding a human inhibitor-of-apoptosis protein; hiap3 |
| 02/17/2000 | WO2000008143A2 Gene isolated on the short arm of human chromosome 17 |
| 02/17/2000 | WO2000008141A2 Short oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | WO2000008140A2 Antisense oligonucleotides for the inhibition of vegf expression |
| 02/17/2000 | WO2000008139A1 Tumor necrosis factor-gamma |
| 02/17/2000 | WO2000008135A1 Methods and compositions for inhibiting or stimulating telomerase assembly |
| 02/17/2000 | WO2000008133A1 NOVEL G PROTEIN-COUPLED RECEPTOR cDNA SEQUENCE |
| 02/17/2000 | WO2000008057A2 Molecules designated b7l-1 |
| 02/17/2000 | WO2000008056A1 NOVEL POLYPEPTIDE, cDNA ENCODING THE SAME AND UTILIZATION THEREOF |
| 02/17/2000 | WO2000008055A1 A human vamp-2 like gene (cbcbmh06) |
| 02/17/2000 | WO2000008053A1 Novel g-protein coupled receptor protein and dna thereof |
| 02/17/2000 | WO2000008051A2 Immunological herpes simplex virus antigens and methods for use thereof |
| 02/17/2000 | WO2000008050A1 Dna encoding human monocyte-macrophage apolipoprotein b receptor gene and protein |
| 02/17/2000 | WO2000008049A1 Cyclic peptides with antagonistic activity specific for bradykinin b2 receptor and formulations containing them |
| 02/17/2000 | WO2000008048A2 Inhibitor of histone deacetylase |
| 02/17/2000 | WO2000008047A1 Depsipeptide derivatives bearing piperazinone rings |
| 02/17/2000 | WO2000008046A1 Monocyclic compounds having nk-2 antagonist action and compositions containing them |
| 02/17/2000 | WO2000008045A2 Novel molecules of the tango-93-related protein family and uses thereof |
| 02/17/2000 | WO2000008033A1 Water soluble prodrugs of hindered alcohols or phenols |
| 02/17/2000 | WO2000008015A2 Fsh mimetics for the treatment of infertility |
| 02/17/2000 | WO2000007979A2 Compounds and compositions for delivering active agents |
| 02/17/2000 | WO2000007659A1 Apparatus and method of preparation of stable, long term thrombin from plasma and thrombin formed thereby |
| 02/17/2000 | WO2000007631A1 Expression and characterization of hiv-1 envelope protein associated with a broadly reactive neutralizing antibody response |
| 02/17/2000 | WO2000007629A2 Peg-urate oxidase conjugates and use thereof |
| 02/17/2000 | WO2000007624A2 Pharmaceutical composition having inhibitory effect on overproduction and accumulation of extracellular matrix |
| 02/17/2000 | WO2000007620A1 Protease inhibitors for use in the treatment of psoriasis |
| 02/17/2000 | WO2000007619A1 Alteration of the cell cycle in vivo, and particularly for inducing apoptosis of tumor cells |
| 02/17/2000 | WO2000007618A2 Anti-apoptotic compositions comprising the r1 subunit of herpes simplex virus ribonucleotide reductase or its n-terminal portion; and uses thereof |
| 02/17/2000 | WO2000007617A1 Use of glp-1 and analogues for preventing type ii diabetes |
| 02/17/2000 | WO2000007616A2 Use of novel agents inducing cell death in synergy with interferons |
| 02/17/2000 | WO2000007615A1 Preparations for the administration of hepatocyte growth factor |
| 02/17/2000 | WO2000007614A1 Remedies for nerve degeneration diseases |
| 02/17/2000 | WO2000007613A1 Remedies for cerebral central lesions with the use of neurotrophic factors |
| 02/17/2000 | WO2000007612A1 Defensins against ocular infection |
| 02/17/2000 | WO2000007611A1 Treatment of central nervous system ischemia or trauma with epidermal growth factor-like polypeptides |
| 02/17/2000 | WO2000007610A1 Interacting proteins for autoantigens of autoimmune diseases |
| 02/17/2000 | WO2000007609A1 Peptide antagonists of zonulin and methods for use of the same |
| 02/17/2000 | WO2000007565A2 Methods of ophthalmic administration |
| 02/17/2000 | WO2000007545A2 Apoptosis proteins |
| 02/17/2000 | WO2000007543A2 Conjugates targeted to the interleukin-2 receptors |
| 02/17/2000 | WO2000007515A1 Improved method for targeted topical treatment of disease |
| 02/17/2000 | WO2000007465A1 Solution for resuscitating multicellular organism cells and method for resuscitating multicellular organism cells by using the same |
| 02/17/2000 | WO2000001815A3 Neurotrophic factors |
| 02/17/2000 | WO2000001720A3 Compositions and methods for treating papillomavirus-infected cells |